Table 6.
Complications and treatments of COVID-19 patients.
| ALL (n = 843) | Group A (n = 324) | Group B (n = 358) | Group C (n = 161) | |
|---|---|---|---|---|
| Complications, No. (%) | 129 (15.3%) | 60 (18.5%) | 51 (14.2%) | 18 (11.2%)* |
| Shock | 50 (5.9%) | 21 (6.5%) | 20 (5.6%) | 9 (5.6%) |
| Acute cardiac injury | 79 (9.4%) | 34 (10.5%) | 34 (9.5%) | 11 (6.8%) |
| Acute renal injury | 11 (1.3%) | 6 (1.9%) | 2 (0.6%) | 3 (1.9%) |
| Acute liver injury | 37 (4.4%) | 18 (5.6%) | 12 (3.4%) | 7 (4.3%) |
| Only one complication | 94 (11.2%) | 46 (14.2%) | 37 (10.3%) | 11 (6.8%)* |
| ≥2 complications | 35 (4.2%) | 14 (4.3%) | 12 (3.4%) | 7 (4.3%) |
| Admission to ICU, No. (%) | 41 (4.9%) | 19 (5.9%) | 17 (4.7%) | 5 (3.1%) |
| Oxygen therapy, No. (%) | ||||
| Nasal catheter oxygen inhalation | 553 (65.6%) | 210 (64.8%) | 235 (65.6%) | 108 (67.1%) |
| Mask oxygen inhalation | 257 (30.5%) | 98 (30.2%) | 120 (33.5%) | 39 (24.2%)# |
| HFBHTI | 63 (7.5%) | 22 (6.8%) | 28 (7.8%) | 13 (8.1%) |
| Non-invasive mechanical ventilation | 105 (12.5%) | 45 (13.9%) | 43 (12%) | 17 (10.6%) |
| Invasive mechanical ventilation | 23 (2.7%) | 10 (3.1%) | 9 (2.5%) | 4 (2.5%) |
| Medical treatment, No. (%) | ||||
| Antiviral treatment | 797 (94.5%) | 294 (90.7%) | 346 (96.6%)* | 157 (97.5%)* |
| Antibiotic treatment | 662 (78.5%) | 245 (75.6%) | 287 (80.2%) | 130 (80.7%) |
| Antifungal treatment | 12 (1.4%) | 3 (0.9%) | 6 (1.7%) | 3 (1.9%) |
| Intravenous glucocorticoids | 391 (46.4%) | 151 (46.6%) | 165 (46.1%) | 75 (46.6%) |
| Immunoglobulin therapy | 430(51.0%) | 175 (54%) | 181 (50.6%) | 74 (46%) |
| Special treatment, No. (%) | ||||
| CRRT | 8 (1.0%) | 3 (0.9%) | 5 (1.4%) | 0 (0%) |
| ECMO | 2 (0.2%) | 1 (0.3%) | 1 (0.3%) | 0 (0%) |
| ALSS | 9 (1.1%) | 2 (0.6%) | 5 (1.4%) | 2 (1.2%) |
Abbreviation: ALSS: artificial liver support system; CRRT: continuous renal replacement therapy; ECMO: extracorporeal membrane oxygenation; ICU: intensive care unit; IQR: interquartile range. * p < 0.05 vs. group A. # p < 0.05 vs. group B.